See more : Palace Banquet Holdings Limited (1703.HK) Income Statement Analysis – Financial Results
Complete financial analysis of eFFECTOR Therapeutics, Inc. (EFTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of eFFECTOR Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sinopec Kantons Holdings Limited (SNPKF) Income Statement Analysis – Financial Results
- THINCA CO LTD (149A.T) Income Statement Analysis – Financial Results
- Croma Security Solutions Group plc (CSSG.L) Income Statement Analysis – Financial Results
- Lowland Investment Company plc (LWI.L) Income Statement Analysis – Financial Results
- Lenovo Group Limited (0992.HK) Income Statement Analysis – Financial Results
eFFECTOR Therapeutics, Inc. (EFTR)
About eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.55M | 1.43M | 42.00M | 0.00 |
| Cost of Revenue | 22.92M | 53.00K | 24.00K | 21.83M | 307.00K |
| Gross Profit | -22.92M | 3.50M | 1.41M | 20.17M | -307.00K |
| Gross Profit Ratio | 0.00% | 98.51% | 98.32% | 48.02% | 0.00% |
| Research & Development | 22.92M | 23.31M | 19.96M | 21.83M | 23.58M |
| General & Administrative | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.93M | 12.64M | 13.37M | 4.35M | 4.72M |
| Other Expenses | 0.00 | -3.55M | -1.43M | 9.00K | 0.00 |
| Operating Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.30M |
| Cost & Expenses | 33.84M | 32.40M | 31.90M | 26.18M | 28.61M |
| Interest Income | 1.95M | 439.00K | 6.00K | 67.00K | 239.00K |
| Interest Expense | 0.00 | 2.25M | 1.76M | 1.33M | 1.38M |
| Depreciation & Amortization | 111.00K | 53.00K | 24.00K | 160.00K | 307.00K |
| EBITDA | -33.73M | -32.40M | -31.90M | 16.06M | -28.30M |
| EBITDA Ratio | 0.00% | -911.99% | -2,230.56% | 38.23% | 0.00% |
| Operating Income | -33.84M | -32.40M | -31.90M | 15.82M | -28.61M |
| Operating Income Ratio | 0.00% | -911.99% | -2,230.56% | 37.66% | 0.00% |
| Total Other Income/Expenses | -1.97M | 9.74M | 47.70M | -1.26M | -1.13M |
| Income Before Tax | -35.81M | -22.67M | 15.80M | 14.56M | -29.74M |
| Income Before Tax Ratio | 0.00% | -637.91% | 1,104.76% | 34.67% | 0.00% |
| Income Tax Expense | 0.00 | -9.74M | -24.00K | 351.00K | 135.14K |
| Net Income | -35.81M | -12.93M | 15.80M | 14.21M | -29.74M |
| Net Income Ratio | 0.00% | -363.83% | 1,104.76% | 33.84% | 0.00% |
| EPS | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| EPS Diluted | -16.37 | -7.85 | 9.78 | 23.74 | -53.83 |
| Weighted Avg Shares Out | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
| Weighted Avg Shares Out (Dil) | 2.19M | 1.65M | 1.62M | 598.56K | 552.43K |
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies
Source: https://incomestatements.info
Category: Stock Reports